Arvinas is developing a new class of drugs that engage the body’s own natural protein disposal system to treat cancers and other difficult-to-treat diseases.
As a potential improvement over traditional small molecule inhibitors, PROTACs (Proteolysis-Targeting Chimeras) are able to degrade disease-causing proteins through the cell’s Ubiquitin/Proteasome System, which routinely removes damaged proteins.
PROTACTM degraders work by recruiting an E3 ligase to tag the target protein for ubiquitination and degradation through the proteasome, a large complex that degrades the ubiquitinated protein into small peptides. After destruction of the protein, the PROTAC is released to continue its seek and destroy mission.
It is similar to our body detoxing during sleep, eating whole foods, exercising and being happy surrounded by nature, good music, good people and a positive spirit.